argenx SE (ETR:1AE)
Germany · Delayed Price · Currency is EUR | Market Cap | 43.16B +37.4% |
| Revenue (ttm) | 4.11B +79.4% |
| Net Income | 1.29B +39.9% |
| EPS | 19.51 +41.1% |
| Shares Out | n/a |
| PE Ratio | 33.42 |
| Forward PE | 26.14 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | n/a |
| Open | 678.20 |
| Previous Close | 713.40 |
| Day's Range | 678.20 - 678.20 |
| 52-Week Range | 574.20 - 806.00 |
| Beta | n/a |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | May 7, 2026 |
About argenx SE
argenx SE, a commercial-stage biopharma company, develops various therapies for the treatment of autoimmune diseases in the United States, Japan, China, the Netherlands, and internationally. The company offers VYVGART for the treatment of gMG and immune thrombocytopenia (ITP), and VYVGART HYTRULO for the treatment of gMG and chronic inflammatory demyelinating polyneuropathy (CIDP). It also develops efgartigimod for the treatment of seronegative gMG, ocular myasthenia gravis (MG), primary ITP, grave’s disease, myositis, Sjögren’s disease, system... [Read more]
Financial Performance
In 2025, argenx SE's revenue was $4.24 billion, an increase of 88.44% compared to the previous year's $2.25 billion. Earnings were $1.29 billion, an increase of 55.10%.
Financial numbers in USD Financial StatementsNews
ArgenX Reports Phase 2 Extension Results For Efgartigimod In Treating Autoimmune Diseases
(RTTNews) - Argenx SE (ARGX), a commercial-stage biopharmaceutical company, announced new clinical data from Phase 2 extension studies for efgartigimod in the treatment of myositis and Sjogren's disea...
Argenx (ARGX) Presents New Vyvgart Data at EULAR 2026 Congress
Argenx (ARGX) Presents New Vyvgart Data at EULAR 2026 Congress
Argenx presents new Vyvgart data at EULAR
Argenx (ARGX) announced the presentation of new data evaluating Vyvgart across autoimmune rheumatic diseases, including myositis and Sjogren’s disease, to be presented at the European Alliance of Asso...
argenx Presents New Efgartigimod Data Showing Long-Term Sustained Patient Benefit in Myositis and Sjogren's Disease at EULAR 2026
ALKIVIA+ data in myositis indicate efgartigimod provides sustained, clinically meaningful improvements and consistent safety RHO+ data in Sjogren's disease indicate maintenance of response following s...
ARGX Maintained by Wells Fargo -- Price Target Raised to $1291
ARGX Maintained by Wells Fargo -- Price Target Raised to $1291
Argenx price target raised to $1,291 from $1,260 at Wells Fargo
Wells Fargo raised the firm’s price target on Argenx (ARGX) to $1,291 from $1,260 and keeps an Overweight rating on the shares. The firm remains constructive into Vyvgart’s Phase 3…
Argenx price target raised to $1,255 from $1,222 at Stifel
Stifel analyst Alex Thompson raised the firm’s price target on Argenx (ARGX) to $1,255 from $1,222 and keeps a Buy rating on the shares. Phase 3 data for the ALKIVIA…
argenx to Host Myositis R&D Webinar on June 23, 2026
May 28, 2026 Amsterdam, the Netherlands – argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today anno...
ARGX Maintained by Evercore ISI Group -- Price Target Raised to $1059
ARGX Maintained by Evercore ISI Group -- Price Target Raised to $1059
Argenx price target raised to $1,059 from $1,007 at Evercore ISI
Evercore ISI analyst Gavin Clark-Gartner raised the firm’s price target on Argenx (ARGX) to $1,059 from $1,007 and keeps an Outperform rating on the shares.
FMR LLC's Strategic Acquisition of Argenx SE Shares
FMR LLC's Strategic Acquisition of Argenx SE Shares
argenx SE at Bank of America Global Healthcare Conference Transcript
argenx SE at Bank of America Global Healthcare Conference Transcript
argenx SE Transcript: Bank of America Global Healthcare Conference 2026
FDA leadership turnover and regulatory uncertainty dominate the policy landscape, with drug pricing reforms and MFN agreements creating long-term industry vulnerabilities. China’s rise in biopharma is accelerating, prompting bipartisan concern but limited immediate legislative action. Expect regulatory focus and oversight to increase post-election, with major reforms unlikely this year.
Argenx price target raised to $1,016 from $1,013 at BofA
BofA analyst Tazeen Ahmad raised the firm’s price target on Argenx (ARGX) to $1,016 from $1,013 and keeps a Buy rating on the shares. Approval of Vyvgart and Vyvgart Hytrulo…
Argenx Wins FDA Nod Expanding VYVGART Label To All Adult GMG Patients
(RTTNews) - argenx SE (ARGX) announced that the U.S. FDA has approved a label expansion for VYVGART (efgartigimod alfa-fcab) and VYVGART Hytrulo (efgartigimod alfa and hyaluronidase-qvfc) for the trea...
argenx (ARGX) Receives FDA Approval for Expanded Vyvgart Label in Myasthenia Gravis
argenx (ARGX) Receives FDA Approval for Expanded Vyvgart Label in Myasthenia Gravis
Argenx (ARGX) Gains FDA Approval for Expanded Vyvgart Use
Argenx (ARGX) Gains FDA Approval for Expanded Vyvgart Use
Argenx: FDA approves label expansion for Vyvgart, Vvygart Hytrulo
Argenx (ARGX) announced the U.S. FDA approved a label expansion for Vyvgart and Vyvgart Hytrulo for the treatment of adult patients with generalized myasthenia gravis. The approved supplemental Biolog...
argenx Announces U.S. FDA Approval Expanding VYVGART and VYVGART Hytrulo for Use in All Adult Patients Living with gMG
VYVGART and VYVGART Hytrulo are the first and only approved treatments for all serotypes of adult patients living with gMG – anti-AChR-Ab positive, anti-MuSK-Ab positive, anti-LRP4-Ab positive, and tr...
ARGX Maintained by Guggenheim -- Price Target Raised to $1135
ARGX Maintained by Guggenheim -- Price Target Raised to $1135
ARGX Maintained by Wells Fargo -- Price Target Raised to $1260
ARGX Maintained by Wells Fargo -- Price Target Raised to $1260
Argenx price target lowered to $1,170 from $1,230 at Morgan Stanley
Morgan Stanley analyst Sean Laaman lowered the firm’s price target on Argenx (ARGX) to $1,170 from $1,230 and keeps an Overweight rating on the shares.
Argenx price target raised to $1,135 from $1,120 at Guggenheim
Guggenheim analyst Yatin Suneja raised the firm’s price target on Argenx (ARGX) to $1,135 from $1,120 and keeps a Buy rating on the shares. The firm adjusted estimates following the…
Argenx price target raised to $1,260 from $1,247 at Wells Fargo
Wells Fargo raised the firm’s price target on Argenx (ARGX) to $1,260 from $1,247 and keeps an Overweight rating on the shares. The firm says Vyvgart’s growth remains durable with…
Argenx price target lowered to $1,222 from $1,227 at Stifel
Stifel lowered the firm’s price target on Argenx (ARGX) to $1,222 from $1,227 and keeps a Buy rating on the shares following an in-line Q1 report. Despite seasonality headwinds, management…